Thus, inhibition of MT1-MMP is a very promising and valuable therapeutic target as it has the potential to increase hepatic LDLR levels, lower circulating LDL-C levels, increase atherosclerotic plaque stability, and reduce the risk of cancer metastasis and invasion. Here, LDLR is linked to cancer.